CASI Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
2025
CASI Pharmaceuticals R&D Spending Growth & History (CASIF)
CASI Pharmaceuticals's r&d spending was $6.3M for fiscal 2025.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.3M | −$2.6M | −29.26% |
| 2024 | 2024-12-31 | $8.9M | −$944,000 | −9.57% |
| 2023 | 2023-12-31 | $9.9M | −$6.1M | −38.35% |
| 2022 | 2022-12-31 | $16.0M | $1.6M | +10.91% |
| 2021 | 2021-12-31 | $14.4M | $3.0M | +25.74% |
| 2020 | 2020-12-31 | $11.5M | — | — |
CASI Pharmaceuticals quarterly r&d spending
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $1.2M | −$2.4M | −66.31% |
| Q3 2025 | 2025-09-30 | $1.4M | — | — |
| Q2 2025 | 2025-06-30 | $1.7M | — | — |
| Q1 2025 | 2025-03-31 | $1.9M | — | — |
| Q4 2024 | 2024-12-31 | $3.7M | — | — |
CASI Pharmaceuticals r&d spending trends
Over the last five fiscal years, CASI Pharmaceuticals's r&d spending decreased from $11.5M to $6.3M, a change of −$5.2M. The latest reported quarter, Q4 2025, shows $1.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗